The Melanoma Research Alliance (MRA) is pleased to announce a Special Opportunity RFP for Team Science Awards focused on patient-centric clinical trials, jointly funded by The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and MRA.
MRA and RTFCCR will jointly support two team awards (each up to $1.5 million) for clinical trials with the potential to provide significant impact to melanoma patients. These awards seek to support novel, interventional clinical trials with the goal of making a significant difference to melanoma patients in the short term. Patient engagement must be actively demonstrated throughout the full life cycle of the clinical trial, including planning and dissemination.
Additional information, including the full RFP and terms and conditions are available on the MRA website at CureMelanoma.org/RFP
- Informational webinars will be offered on July 26 at 9 am ET & July 28 at 11 AM ET. Applicants are highly encouraged to attend.
- Letters of Intent due 11:59 pm ET, October 5, 2022
- Estimated LOI decisions: November 18, 2022
- Invited Full Proposals due 11:59 pm ET, January 18, 2023
Letters of Intent are due on October 5, 2022 by 11:59 PM ET and should be submitted via the proposalCENTRAL online application tool: https://proposalcentral.com.
We strongly encourage you to share this RFP with your colleagues who might want to apply for funding. Please also inform us of others who might not be on our email list who should receive this announcement.